Skip to main content
Premium Trial:

Request an Annual Quote

Cambrex Buys Immortalized Cell Line Assets from XCellsyz

NEW YORK, Jan. 18 (GenomeWeb News) - Cambrex subsidiary Cambrex Bio Science Wokingham will buy conditionally immortalized cell lines and related intellectual property and equipment from British biotech Xcellsyz, Cambrex said today.

 

Financial terms of the deal were not disclosed.

 

Last week, Cambrex signed a worldwide licensing pact with Geron that will see it develop its own immortalized cell lines for distribution using Geron's human telomerase reverse transcriptase technology. XCellsyz last year had signed a similar agreement for Geron's telomerase technology, which it used to develop its own immortalized cell lines.

 

Cambrex said it will use the recently acquired technologies to immortalize a broad set of cell types, which it will sell to researchers for a variety of applications, including cell-based high-throughput drug screening and toxicity testing.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.